AgomAb Therapeutics (NASDAQ:AGMB) Stock Price Down 4.5% – Here’s Why

AgomAb Therapeutics NV (NASDAQ:AGMB) shares traded down 4.5% during mid-day trading on Wednesday . The stock traded as low as $15.14 and last traded at $15.19. 64,273 shares were traded during mid-day trading, a decline of 64% from the average session volume of 177,089 shares. The stock had previously closed at $15.90.

Wall Street Analysts Forecast Growth

AGMB has been the subject of a number of research reports. JPMorgan Chase & Co. assumed coverage on AgomAb Therapeutics in a research note on Tuesday. They issued an “overweight” rating and a $32.00 price objective for the company. Wall Street Zen raised AgomAb Therapeutics to a “hold” rating in a research report on Tuesday, February 17th. Leerink Partners assumed coverage on shares of AgomAb Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $36.00 price target on the stock. Finally, Morgan Stanley started coverage on shares of AgomAb Therapeutics in a report on Tuesday. They issued an “overweight” rating and a $28.00 price objective for the company. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $32.00.

AgomAb Therapeutics Stock Down 5.9%

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.